Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: IRD001
MIFTS: 49

Iridocyclitis

Categories: Eye diseases, Neuronal diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Iridocyclitis

About this section

MalaCards integrated aliases for Iridocyclitis:

Name: Iridocyclitis 11 75 53 43 14 71 75 31
Primary Iridocyclitis 11 71

Classifications:

MalaCards categories:
Anatomical: Eye diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:9383
ICD9CM 34 364.01 364.2
MeSH 43 D015863
SNOMED-CT 68 193485000 193496008
ICD10 31 H20 H20.9 H22.1
UMLS 71 C0007832 C0022073 C0154909
Sources

Summaries for Iridocyclitis

About this section

MalaCards based summary: Iridocyclitis, also known as primary iridocyclitis, is related to infectious anterior uveitis and fuchs' heterochromic uveitis. An important gene associated with Iridocyclitis is DEK (DEK Proto-Oncogene), and among its related pathways/superpathways are Innate Immune System and MIF Mediated Glucocorticoid Regulation. The drugs Lidocaine and Certolizumab pegol have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and growth/size/body region

Wikipedia: 75 Uveitis (/ˌjuːvɪaɪtɪs/) is inflammation of the uvea, the pigmented layer of the eye between the inner... more...
Sources

Related Diseases for Iridocyclitis

About this section

Diseases related to Iridocyclitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1007)
# Related Disease Score Top Affiliating Genes
1 infectious anterior uveitis 32.3 TNF IL17A
2 fuchs' heterochromic uveitis 32.3 IL6 IL10 CXCL8 ACE
3 retinal vasculitis 31.5 VEGFA TNF RBP3 CD4 ACE
4 sympathetic ophthalmia 30.7 TNF RBP3 IL17A IL10 HLA-DRB1 CD4
5 glaucomatocyclitic crisis 30.4 MRAP HLA-B
6 panophthalmitis 30.2 RBP3 CRP CD4
7 cataract 30.2 VEGFA TNF IL6 CXCL8 CRP ACE
8 systemic onset juvenile idiopathic arthritis 30.2 IL6 HLA-DRB1
9 toxoplasmosis 30.1 TNF IL6 IL1B IL17A IL10
10 keratopathy 30.1 VEGFA IL6 CXCL8
11 scleritis 30.1 TNFAIP3 TNF CRP
12 deep keratitis 30.1 RBP3 CRP
13 macular dystrophy, dominant cystoid 30.0 VEGFA TNF RBP3 IL6 ACE
14 conjunctivitis 30.0 TNF IL6 IL10 HLA-B CXCL8
15 pars planitis 30.0 RBP3 HLA-DRB1 HLA-B ACE
16 arthropathy 29.9 TNF IL6 IL1B CRP
17 chikungunya 29.9 TNF IL6 IL1B IL17A CRP
18 cat-scratch disease 29.9 CRP CD4 ACE
19 rubeosis iridis 29.9 VEGFA IL6
20 lepromatous leprosy 29.9 TNF IL10 CD8A CD4
21 interstitial nephritis 29.8 TNF CRP CD8A CD4 ACE
22 purulent endophthalmitis 29.8 VEGFA RBP3 CRP CD4
23 retinal detachment 29.8 VEGFA TNF IL6 IL10 CXCL8
24 drug allergy 29.8 HLA-B CRP CD4 ACE
25 neuroretinitis 29.7 VEGFA CRP CD4 ACE
26 optic papillitis 29.7 TNF RBP3 MRAP CRP CD4 ACE
27 parotitis 29.7 CRP CD8A CD4
28 cartilage disease 29.7 TNF IL6 IL1B CRP
29 toxocariasis 29.7 IL6 IL10 CRP ACE
30 neovascular glaucoma 29.7 VEGFA IL6 CXCL8
31 macular retinal edema 29.6 VEGFA TNF IL6 IL1B CXCL8 ACE
32 macular holes 29.6 VEGFA IL6 CXCL8
33 vitiligo-associated multiple autoimmune disease susceptibility 1 29.6 TNF IL17A HLA-B CD8A CD4
34 leptospirosis 29.6 TNF IL6 IL1B IL10 CXCL8 CRP
35 corneal ulcer 29.6 VEGFA TNF IL6 IL1B
36 intermediate uveitis 29.6 TNF RBP3 IL6 IL17A CD4 ACE
37 secondary syphilis 29.6 TNF CRP CD8A CD4 ACE
38 cysticercosis 29.6 IL6 IL1B IL10 CD4
39 juvenile rheumatoid arthritis 29.5 TNF IL6 IL1B HLA-DRB1 HLA-DPB1 DEK
40 immunoglobulin alpha deficiency 29.5 IL10 CD8A CD4
41 herpes zoster 29.5 IL10 HLA-DRB1 HLA-B CD8A CD4
42 reactive arthritis 29.5 TNF MRAP IL17A HLA-B ERAP1 CRP
43 vascular dementia 29.4 VEGFA TNF IL6 IL1B ACE
44 bell's palsy 29.3 TNF IL6 CRP CD8A CD4 ACE
45 facial paralysis 29.3 TNF IL6 CRP CD8A CD4 ACE
46 giardiasis 29.3 IL17A IL10 CD8A CD4
47 choroiditis 29.3 VEGFA TNF RBP3 IL17A IL10 CRP
48 bartonellosis 29.3 VEGFA CRP CD8A CD4 ACE
49 localized scleroderma 29.2 TNF IL6 IL17A CD8A CD4
50 endophthalmitis 29.2 VEGFA TNF RBP3 IL6 IL1B CXCL8

Graphical network of the top 20 diseases related to Iridocyclitis:



Diseases related to Iridocyclitis
Sources

Symptoms & Phenotypes for Iridocyclitis

About this section

GenomeRNAi Phenotypes related to Iridocyclitis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.13 ACE CD4 CD8A CRP CXCL8 DEK
2 no effect GR00402-S-2 10.13 ACE CD4 CRP DEK ERAP1 HLA-B
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 CXCL8 IL10 IL17A IL1B TNF TNFAIP3
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 ACE CXCL8 IL10 IL17A IL1B TNF

MGI Mouse Phenotypes related to Iridocyclitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.22 ACE CD4 ERAP1 HLA-B HLA-DRB1 IL10
2 endocrine/exocrine gland MP:0005379 10.15 ACE CD4 CD8A ERAP1 HLA-B IL10
3 liver/biliary system MP:0005370 10.09 ACE ERAP1 IL10 IL17A IL6 MRAP
4 immune system MP:0005387 10.07 ACE CD4 CD8A CRP ERAP1 HLA-B
5 no phenotypic analysis MP:0003012 10.06 CD4 ERAP1 HLA-B IL10 IL17A TNF
6 neoplasm MP:0002006 10.02 ACE DEK IL10 IL1B IL6 TNF
7 digestive/alimentary MP:0005381 9.92 CD4 HLA-B IL10 IL17A IL6 TNF
8 skeleton MP:0005390 9.85 ERAP1 HLA-DRB1 IL10 IL17A IL1B IL6
9 hematopoietic system MP:0005397 9.73 ACE CD4 CD8A ERAP1 HLA-B IL10
10 integument MP:0010771 9.32 CD4 CD8A IL10 IL17A IL1B IL6
Sources

Drugs & Therapeutics for Iridocyclitis

About this section

Drugs for Iridocyclitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 87)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Certolizumab pegol Approved Phase 4 428863-50-7
3
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
4 BB 1101 Phase 4
5 Anesthetics Phase 4
6 Antirheumatic Agents Phase 4
7 Immunosuppressive Agents Phase 4
8 Immunologic Factors Phase 4
9 Ophthalmic Solutions Phase 4
10 Anti-Infective Agents Phase 4
11 Antiviral Agents Phase 4
12 Ganciclovir triphosphate Phase 4
13 Hormones Phase 4
14 Hormone Antagonists Phase 4
15 Melanocyte-Stimulating Hormones Phase 4
16 Adrenocorticotropic Hormone Phase 4
17
beta-Endorphin Phase 4
18
Difluprednate Approved Phase 3 23674-86-4 443936
19
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
20
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
21
Prednisolone Approved, Vet_approved Phase 3 50-24-8 4894 5755
22
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5 1875
23
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 4159 6741
24
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961
25
Valganciclovir Approved, Investigational Phase 2, Phase 3 175865-60-8 64147
26
Isoniazid Approved, Investigational Phase 3 54-85-3 3767
27
Pyrazinamide Approved, Investigational Phase 3 98-96-4 1046
28
Fluorometholone Approved, Investigational Phase 3 426-13-1 9878
29
Phenylephrine Approved Phase 3 59-42-7 6041
30
Ethambutol Approved Phase 3 74-55-5, 1070-11-7 3279 14052
31
Tropicamide Approved, Investigational Phase 3 1508-75-4 5593
32
Dipivefrin Approved Phase 3 52365-63-6 3105
33
Oxymetazoline Approved, Investigational Phase 3 1491-59-4 4636
34
Rifampicin Approved Phase 3 13292-46-1 135512673 5381226 135900090
35
Atropine Approved, Vet_approved Phase 3 101-31-5, 5908-99-6, 51-55-8 3661 154417 174174
36
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3 3680
37
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 3003 5743
38
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
39
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7 4897
40 Neuroprotective Agents Phase 3
41 Dexamethasone 21-phosphate Phase 3
42
Methylprednisolone Acetate Phase 3 584547
43 Protective Agents Phase 3
44 Benzalkonium Compounds Phase 3
45 Calcium, Dietary Phase 3
46 Anticoagulants Phase 3
47 Anti-Infective Agents, Local Phase 3
48 Citrate Phase 3
49 Chelating Agents Phase 3
50 Pharmaceutical Solutions Phase 2, Phase 3

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 Evaluation of DEXTENZA on the Management of Pain and Inflammation in Patients With Anterior Uveitis Compared to Standard of Care Topical Corticosteroids Unknown status NCT04426734 Phase 4 Topical Prednisolone Acetate 1%
2 Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW) Completed NCT03020992 Phase 4 Certolizumab Pegol
3 Prospective Open Label Study of H.P. Acthar Gel Injection in Patients With Active Non-Infectious Uveitis With Associated Glaucoma Thus High Frequency Regional Corticosteroid and Oral Corticosteroids Cause Intolerable Side-Effects Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
4 Intra-cameral Penetration and Efficacy of Ganciclovir Following Topical Administration of 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
5 Prospective Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis Who Are Not Well Controlled With, or Intolerant of, Topical or Systemic Corticosteroids Terminated NCT02769702 Phase 4 Acthar
6 Phase 3 Confirmatory Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Anterior Uveitis (Including Panuveitis). Completed NCT00406887 Phase 3 Difluprednate Ophthalmic Emulsion
7 A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Anterior Uveitis Completed NCT00404885 Phase 3 Placebo;LX211
8 A Phase 3, Randomized, Double-masked, Vehicle-controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis. Completed NCT03131154 Phase 3 ADX-102 Ophthalmic Solution (0.5%);Vehicle of ADX-102 Ophthalmic Solution
9 A Prospective, Multi-Center, Randomized, Double-Masked, Positive Controlled, Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis Completed NCT02517619 Phase 3 Dexamethasone Phosphate Ophthalmic Solution;Prednisolone Acetate Ophthalmic (1%)
10 A Phase 3 Multicenter, Randomized, Double-Masked Study of the Safety and Efficacy of Difluprednate 0.05% Ophthalmic Emulsion Compared to Prednisolone Acetate 1% Ophthalmic Suspension in the Treatment of Endogenous Anterior Uveitis Completed NCT01201798 Phase 3 Difluprednate 0.05% ophthalmic emulsion;Prednisolone acetate 1.0% ophthalmic suspension
11 A Prospective, Multi-Center, Randomized, Double-Masked, Positive-Controlled Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis Completed NCT01505088 Phase 3 40 mg/mL Dexamethasone phosphate ophthalmic solution;Prednisolone Acetate (1%) Eyedrops;100 mM sodium citrate buffer solution;Placebo Eyedrops
12 A Phase 3 Randomized, Active-Controlled, Double-Masked Study to Evaluate the Safety and Efficacy of TRS01 Eye Drops in the Treatment of Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma Recruiting NCT05042609 Phase 3 TRS01;FDA approved steroid eye drop
13 Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Recruiting NCT03586284 Phase 2, Phase 3 Valganciclovir Hydrochloride;Ganciclovir Sodium;Placebo Oral Tablet;Topical placebo
14 Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA) Not yet recruiting NCT04117698 Phase 3 Antitubercular treatment (RIFATER ©);Ethambutol;RIFINAH ©
15 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis Terminated NCT00333996 Phase 2, Phase 3 Dexamethasone
16 Phase 2a Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Anterior Uveitis (Inluding Iritis, Cyclitis, Iridocyclitis, and Panuveitis). Completed NCT00405496 Phase 2 Difluprednate Ophthalmic Emulsion
17 A Randomized, Parallel Group, Double-masked, Active-controlled Phase 1/2 Clinical Trial to Evaluate the Efficacy and Safety of Dexamethasone Sodium Phosphate Visulex System for the Treatment of Non-infectious Anterior Uveitis Completed NCT02309385 Phase 1, Phase 2 8% Dexamethasone Sodium Phosphate - Visulex;15% Dexamethasone Sodium Phosphate - Visulex;Prednisolone Acetate (1%) Eye Drops
18 A Randomized, Double-Masked, Dose-Ranging Study to Evaluate the Safety and Tolerability of TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis. Completed NCT04222712 Phase 1, Phase 2 TRS01 eye drops
19 An Open Label Exploratory Study to Assess the Safety, Tolerability and Clinical Activity of Topically Applied ESBA105 in Patients With Acute Anterior Uveitis Completed NCT00823173 Phase 2
20 Treatment of Active Anterior Uveitis Associated With JIA, Using Humanized Anti-Tac (HAT, Daclizumab) Completed NCT00130637 Phase 2 Daclizumab
21 A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients With Anterior Uveitis Completed NCT02406209 Phase 2 NS2;Prednisolone acetate ophthalmic suspension (1%)
22 A Multicenter, Randomized, Double-Masked, Active-Controlled Study to Evaluate the Safety and Efficacy of LME636 in Patients With Acute Anterior Uveitis Completed NCT02482129 Phase 2 LME636 60 mg/mL ophthalmic solution;Dexamethasone 0.1% ophthalmic solution;LME636 Vehicle
23 The Treatment of Macular Edema Secondary to Uveitis Using Topical Interferon Gamma Completed NCT01376362 Phase 1, Phase 2 Interferon Gamma-1b
24 Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveitis Completed NCT00876434 Phase 1 Sirolimus
25 Pathogen Detection in Infectious Uveitis in China Unknown status NCT04521673
26 Pilot Project: The Amplicon and Metatranscriptomic Next-generation Sequencing of Samples From Intra and Extra-intestinal Microbiome in Non-infectious Uveitis Patients to Decipher Possibility Uveitis Pathogenesis Unknown status NCT04126850
27 Quality of Life and Visual Function in Uveitis Patients Unknown status NCT00407316
28 Acute Anterior Uveitis: Psychic Burden and Pain Unknown status NCT01156285
29 Clinical Outcomes of Topical Ganciclovir Treatment in Cytomegalovirus Anterior Uveitis Unknown status NCT01486693
30 Prevalence of Ocular Manifestations in Inflammatory Rheumatic Diseases Completed NCT03753893
31 Retinal Optical Coherence Tomography and Multifocal Electroretinogram; Establishing Normal Ranges Related to Age and Reproductive Factors; With the Use of Anti-inflammatory Medications;In Uncomplicated Anterior Uveitis; Anatomy and Function. Completed NCT00476593 Diclofenac;Dexamethasone
32 Evaluation and Treatment Protocol for Patients With Intraocular Inflammatory Disease (Uveitis) Completed NCT00006188
33 The Contribution of Altered Aqueous Dynamics in the Development of Raised Intraocular Pressure in Patients With Uveitis Completed NCT02765308
34 Ocular Sarcoidosis Open Label Trial of ACTHAR Gel Completed NCT02725177 Repository Corticotropin Injection;Repository Corticotropin Injection -Treatment Extension
35 Efficacy and Adverse Effects of Cyclosporine A in the Treatment of Chronic Anterior Uveitis in Patients With Juvenile Idiopathic Arthritis Completed NCT00404482 Cyclosporine A
36 Intra-cameral Penetration of Ganciclovir Following Topical Administration of 0.15% Ganciclovir Gel (VIRGAN©) for CMV Anterior Uveitis / Endotheliitis Completed NCT01647529 Ganciclovir
37 PEMF an Adjunct Therapy for Anterior Uveitis Completed NCT01154010
38 Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate Uveitis Completed NCT02879084
39 German Spondyloarthritis Inception Cohort Recruiting NCT01277419

Search NIH Clinical Center for Iridocyclitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Scopolamine
Scopolamine Hydrobromide
Tropicamide

Cochrane evidence based reviews: iridocyclitis

Sources

Genetic Tests for Iridocyclitis

About this section
Sources

Anatomical Context for Iridocyclitis

About this section

Organs/tissues related to Iridocyclitis:

MalaCards : Eye, Retina, Endothelial, Lymph Node, Skin, Testes, Brain
Sources

Publications for Iridocyclitis

About this section

Articles related to Iridocyclitis:

(show top 50) (show all 1312)
# Title Authors PMID Year
1
Antibodies to the 45 kDa DEK nuclear antigen in pauciarticular onset juvenile rheumatoid arthritis and iridocyclitis: selective association with MHC gene. 53 62
9058666 1997
2
Inflammatory ocular events after inactivated COVID-19 vaccination. 62
36369840 2022
3
Atypical herpes zoster ophthalmicus with madarosis of upper eyelid, recurrent iridocyclitis and atrophic multifocal chorioretinopathy. 62
36314406 2022
4
T Helper 2 IL-4/IL-13 Dual Blockade with Dupilumab Is Linked to Some Emergent T Helper 17‒Type Diseases, Including Seronegative Arthritis and Enthesitis/Enthesopathy, but Not to Humoral Autoimmune Diseases. 62
35395222 2022
5
Clinical characteristics in the misdiagnosis of cytomegalovirus retinitis: A retrospective analysis of eight patients. 62
36190053 2022
6
Snowflakes in the Eye - An Uncommon Presentation of Iris Metastasis of Esophageal Carcinoma and Review of Literature. 62
34003704 2022
7
COVID-19-related bilateral acute de-pigmentation of iris with ocular hypertension. 62
35918989 2022
8
Development and Validation of a Model to Predict Anterior Segment Vision-Threatening Eye Disease Using Primary Care Clinical Notes. 62
34620768 2022
9
Optic coherence tomography angiography findings in fuchs heterochromic iridocyclitis. 62
35624335 2022
10
Causal analysis of serum polyunsaturated fatty acids with juvenile idiopathic arthritis and ocular comorbidity. 62
35974138 2022
11
A CASE REPORT OF CHRONIC ENDOPHTHALMITIS SECONDARY TO AQUAMICROBIUMterrae. 62
32349062 2022
12
Ocular Inflammatory Reactions following an Inactivated SARS-CoV-2 Vaccine: A Four Case Series. 62
35819841 2022
13
Treatment of Complications Due to Fuchs Heterochromic Iridocyclitis (FHI) - a Case Report. 62
35774838 2022
14
Analysis of Patients With Blowout Fracture Caused by Baseball Trauma. 62
36041113 2022
15
XEN® 63 gel stent to treat a refractory uveitic glaucoma: A case report. 62
35711166 2022
16
Novel disease-causing variants and phenotypic features of X-linked megalocornea. 62
34644435 2022
17
OP-4 Descemet membrane endothelial keratoplasty patching (DMEP) - selective endothelial replacement in eyes with localised endothelial dysfunction. 62
36161812 2022
18
Clinical Findings of Specular Microscopy Images in Cytomegalovirus Corneal Endotheliitis. 62
35772085 2022
19
Eye-related emergency visits during the early phase of the coronavirus disease pandemic in a reference hospital in Sao Paulo, Brazil. 62
35319652 2022
20
Intraocular inflammation secondary to intravitreal brolucizumab treated successfully with Sub-Tenon triamcinolone: A case report. 62
35146186 2022
21
Clinical Spectrum and CSF Findings in Patients with West-Nile Virus Infection, a Retrospective Cohort Review. 62
35453853 2022
22
A new approach to categorization of ocular injury among U.S. Armed Forces. 62
35442608 2022
23
Cytokine Changes in the Aqueous Humor in Rubella-Related Fuchs Heterochromic Iridocyclitis. 62
35178133 2022
24
Sociodemographic Factors and Comorbidities Including Hyperparathyroidism Are Associated With an Increased Risk of Band Keratopathy: A Population-Based Study in Taiwan. 62
35784561 2022
25
Bilateral Granulomatous Iridocyclitis Associated with Early-Onset Juvenile Psoriatic Arthritis. 62
36249177 2022
26
Mendelian Randomization Study Implies Causal Linkage Between Telomere Length and Juvenile Idiopathic Arthritis in a European Population. 62
35210806 2022
27
What's Eating You? Caterpillars. 62
35167790 2021
28
Neurotrophic corneal ulcer and iridocyclitis directly preceding Ramsay-Hunt Syndrome. 62
34786517 2021
29
A comprehensive review of machine learning techniques on diabetes detection. 62
34862560 2021
30
Clinical Features and Visual Outcome of Uveitis in Japanese Patients Younger than 18 Years. 62
32162972 2021
31
Establishing an Animal Model of Cytomegalovirus Keratouveitis in Rats: Broad Infection of Anterior Segment Tissue by Cytomegalovirus. 62
34698772 2021
32
Assessing the Uniformity of Uveitis Clinical Concepts and Associated ICD-10 Codes Across Health Care Systems Sharing the Same Electronic Health Records System. 62
34196692 2021
33
Adverse Events of Intense Pulsed Light Combined With Meibomian Gland Expression Versus Meibomian Gland Expression in the Treatment of Meibomian Gland Dysfunction. 62
33161597 2021
34
Changes in Etiology of Uveitis in a Single Center in Japan. 62
32068467 2021
35
Incidence and changing patterns of uveitis in Central Tokyo. 62
34047908 2021
36
A prediction rule for polyarticular extension in oligoarticular-onset juvenile idiopathic arthritis. 62
34001309 2021
37
Aetiology and clinical characteristics of uveitic glaucoma in Turkish patients. 62
33730317 2021
38
Ocular tuberculosis in a calf. 62
33964902 2021
39
Intraocular Endoscopy Resolved Tube Occlusion of an Ahmed Glaucoma Valve. 62
34594208 2021
40
Diagnosis of cytomegalovirus corneal endotheliitis using surgically removed Descemet's membrane and endothelium despite negative results with aqueous humor PCR: a case report. 62
33933006 2021
41
Assessment of spontaneous brain activity patterns in patients with iridocyclitis: a resting-state study. 62
33789337 2021
42
[The safety of atropine for myopia prevention and control]. 62
33832055 2021
43
Atypical Granulomatosis with Polyangiitis Presenting with Meibomitis, Scleritis, Uveitis and Papillary Bladder Tumor: A Case Report and Literature Review. 62
33918928 2021
44
Clinical, pathological and virological aspects of fatal West Nile virus infections in ten free-ranging goshawks (Accipiter gentilis) in Germany. 62
32743905 2021
45
Delayed diagnosis of myelitis in a patient with Vogt-Koyanagi-Harada disease: a case report. 62
33788652 2021
46
Clinical Features and Diagnosis of Anterior Segment Inflammation Related to Cytomegalovirus in Immunocompetent African, Asian, and Caucasian Patients. 62
31642720 2021
47
Clinical Profile of COVID-19 Patients Presenting with Uveitis - A Short Case Series. 62
34188557 2021
48
The Spanish Composer Manuel de Falla and His Eyes: The Musical Brain. 62
34723184 2021
49
Altered Functional Connectivity of the Primary Visual Cortex in Patients With Iridocyclitis and Assessment of Its Predictive Value Using Machine Learning. 62
34025659 2021
50
Case Report: Associated Ocular Adverse Reactions With Inactivated COVID-19 Vaccine in China. 62
35111790 2021
Sources

Variations for Iridocyclitis

About this section
Sources

Expression for Iridocyclitis

About this section
Search GEO for disease gene expression data for Iridocyclitis.
Sources

Pathways for Iridocyclitis

About this section

Pathways related to Iridocyclitis according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.92 CD4 CD8A CRP CXCL8 ERAP1 HLA-B
2
MIF Mediated Glucocorticoid Regulation 64
Show member pathways
 13.63 VEGFA TNF IL6 IL1B IL17A IL10
3
TGF-Beta Pathway 64
Show member pathways
 13.54 VEGFA TNF IL6 IL1B IL17A IL10
4
Akt Signaling 64
Show member pathways
 13.4 TNF IL6 IL1B IL17A IL10 CXCL8
5
PAK Pathway 64
Show member pathways
 13.3 CD4 CXCL8 IL10 IL17A IL1B IL6
6
Cytokine Signaling in Immune system 66
Show member pathways
 13.28 VEGFA TNF IL6 IL1B IL17A IL10
7
Toll-like receptor signaling pathway 74
Show member pathways
 12.84 TNFAIP3 TNF IL6 IL1B CXCL8
8
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.67 TNF IL6 IL1B IL17A IL10 HLA-B
9
Immune response IL-23 signaling pathway 22
Show member pathways
 12.64 TNF IL6 IL1B IL17A IL10 CD4
10
NF-kappaB Signaling 3
12.61 CD8A IL10 IL17A IL1B TNF TNFAIP3
11
Toll-Like receptor Signaling Pathways 65
Show member pathways
 12.51 CXCL8 IL1B IL6 TNF
12
Bacterial infections in CF airways 22
Show member pathways
 12.41 TNF IL6 IL1B CXCL8
13
CD28 co-stimulation 66
Show member pathways
 12.39 HLA-DRB1 HLA-DPB1 CD8A CD4
14
Toll Comparative Pathway 64
Show member pathways
 12.32 TNF IL6 IL1B CXCL8
15
IL-17 Family Signaling Pathways 65
Show member pathways
 12.28 TNF IL6 IL17A CXCL8
16
Sudden infant death syndrome (SIDS) susceptibility pathways 74
12.23 VEGFA TNF IL6 IL1B IL10 CXCL8
17
T-cell activation SARS-CoV-2 74
Show member pathways
 12.18 TNF IL17A IL10 HLA-DRB1 CD8A CD4
18
Neuroinflammation and glutamatergic signaling 74
12.12 TNF IL6 IL1B IL10
19
Hematopoietic Stem Cells and Lineage-specific Markers 65
12.07 TNF IL6 IL10 CD8A CD4
20
Spinal cord injury 74
12.03 TNF IL6 IL1B CXCL8
21
CCL18 signaling pathway 74
11.95 VEGFA IL6 IL10 CXCL8
22
IL27-mediated signaling events 61
Show member pathways
 11.95 TNF IL6 IL1B IL17A IL10 CD4
23
Th17 Differentiation 65
Show member pathways
 11.91 CD4 IL17A IL1B IL6
24
Interleukin-4 and Interleukin-13 signaling 66
11.9 VEGFA TNF IL6 IL1B IL17A IL10
25
Burn wound healing 74
11.84 VEGFA TNF IL6 IL1B CXCL8
26
Innate Lymphoid Cells Differentiation 65
11.81 TNF IL1B IL17A IL10 CD8A CD4
27
Extrafollicular B cell activation by SARS-CoV-2 74
11.8 TNF IL6 IL10 CRP
28
Phosphorylation of CD3 and TCR zeta chains 66
Show member pathways
 11.79 HLA-DRB1 HLA-DPB1 CD4
29
Th17 cell differentiation pathway 74
11.79 IL6 IL1B IL17A CD4
30
Network map of SARS-CoV-2 signaling pathway 74
Show member pathways
 11.77 IL6 HLA-DRB1 CXCL8 CRP CD8A CD4
31
Acute viral myocarditis 74
11.75 IL6 IL10 CD4
32
Lung fibrosis 74
11.74 TNF IL6 IL1B CXCL8
33
miRNAs involvement in the immune response in sepsis 74
11.73 TNF IL6 IL10 CXCL8
34
IL 10 signaling pathway 67
11.73 TNF IL6 IL1B IL10
35
Photodynamic therapy-induced NF-kB survival signaling 74
Show member pathways
 11.73 VEGFA TNF IL6 IL1B CXCL8
36
AP-1 transcription factor network 61
11.72 IL6 IL10 CXCL8
37
Dendritic Cells Developmental Lineage Pathway 65
11.71 CD4 CD8A IL10 IL1B IL6 TNF
38
Inflammatory bowel disease signaling 74
Show member pathways
 11.64 TNF IL6 IL10
39
Hepatitis C and hepatocellular carcinoma 74
11.61 VEGFA IL6 CXCL8
40
THC Differentiation Pathway 64
11.61 TNF IL10 HLA-DRB1 HLA-DPB1 CD4
41
Interleukin-10 signaling 66
11.58 TNF IL6 IL1B IL10 CXCL8
42
SARS-CoV-2 innate immunity evasion and cell-specific immune response 74
11.57 TNF IL10 CXCL8
43
Non-genomic actions of 1,25 dihydroxyvitamin D3 74
11.57 TNF IL6 CXCL8
44
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.51 TNF IL6 IL1B
45
IL-10 Pathway 64
11.44 TNF IL6 IL1B IL10
46
Heparin-induced Thrombocytopenia Pathway, Adverse Drug Reaction 60
11.42 IL10 HLA-DRB1 CD4
47
Development and heterogeneity of the ILC family 74
11.4 TNF IL6 IL1B IL17A
48
Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway 74
11.35 TNF IL6 IL1B CXCL8
49
Allograft rejection 74
11.24 VEGFA TNF IL1B IL17A IL10 HLA-DRB1
50
Cytokines and inflammatory response 74
11.2 TNF IL6 IL1B IL10 HLA-DRB1 CD4
Sources

GO Terms for Iridocyclitis

About this section

Cellular components related to Iridocyclitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.23 ACE CD8A CRP CXCL8 ERAP1 IL10
2 external side of plasma membrane GO:0009897 10.03 TNF IL17A HLA-DRB1 CD8A CD4 ACE
3 extracellular space GO:0005615 9.7 VEGFA TNF RBP3 IL6 IL1B IL17A
4 obsolete integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.13 HLA-DRB1 HLA-DPB1 HLA-B

Biological processes related to Iridocyclitis according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.56 CD4 CXCL8 DEK ERAP1 HLA-DRB1 IL10
2 positive regulation of gene expression GO:0010628 10.44 VEGFA TNF IL6 IL1B CXCL8 CRP
3 inflammatory response GO:0006954 10.32 TNFAIP3 TNF IL6 IL1B IL17A CXCL8
4 adaptive immune response GO:0002250 10.31 CD4 CD8A ERAP1 HLA-B HLA-DPB1 HLA-DRB1
5 positive regulation of protein phosphorylation GO:0001934 10.3 VEGFA TNF IL1B HLA-DRB1 CD4
6 positive regulation of DNA-binding transcription factor activity GO:0051091 10.25 TNF IL6 IL1B IL10
7 positive regulation of interleukin-6 production GO:0032755 10.21 TNF IL6 IL1B IL17A
8 positive regulation of MAPK cascade GO:0043410 10.19 VEGFA TNF IL6 HLA-DRB1 CD4
9 regulation of insulin secretion GO:0050796 10.15 TNF IL6 IL1B
10 response to activity GO:0014823 10.14 TNF IL6 IL10
11 defense response to Gram-positive bacterium GO:0050830 10.13 CRP IL17A IL1B IL6 TNF
12 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.12 TNF IL6 IL10
13 positive regulation of T cell activation GO:0050870 10.1 HLA-DRB1 HLA-DPB1 CD4
14 liver regeneration GO:0097421 10.09 TNF IL6 IL10
15 positive regulation of cytokine production involved in inflammatory response GO:1900017 10.07 TNF IL6 IL17A
16 positive regulation of chemokine production GO:0032722 10.06 TNF IL6 IL1B
17 negative regulation of neurogenesis GO:0050768 10.06 TNF IL6 IL1B
18 macrophage differentiation GO:0030225 10.05 VEGFA HLA-DRB1 CD4
19 immune system process GO:0002376 10.05 IL17A HLA-DRB1 HLA-DPB1 HLA-B ERAP1 CD8A
20 positive regulation of glial cell proliferation GO:0060252 10.02 TNF IL6 IL1B
21 positive regulation of heterotypic cell-cell adhesion GO:0034116 10 TNF IL1B IL10
22 negative regulation of cytokine production involved in immune response GO:0002719 9.96 IL10 TNF
23 positive regulation of fever generation GO:0031622 9.95 TNF IL1B
24 sequestering of triglyceride GO:0030730 9.94 TNF IL1B
25 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.92 VEGFA ACE
26 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.91 IL1B TNF
27 response to molecule of bacterial origin GO:0002237 9.88 TNFAIP3 IL10 CXCL8
28 chronic inflammatory response to antigenic stimulus GO:0002439 9.87 IL10 TNF
29 negative regulation of gap junction assembly GO:1903597 9.86 ACE IL1B
30 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.85 HLA-B ERAP1 ACE
31 positive regulation of neuroinflammatory response GO:0150078 9.85 TNF IL6 IL1B
32 negative regulation of lipid storage GO:0010888 9.8 TNF IL6 CRP
33 cellular response to lipopolysaccharide GO:0071222 9.7 TNFAIP3 TNF IL6 IL1B IL10 CXCL8
34 antigen processing and presentation GO:0019882 9.65 HLA-DRB1 HLA-DPB1 HLA-B CD8A
35 vascular endothelial growth factor production GO:0010573 9.63 IL1B IL6 TNF
36 immune response GO:0006955 9.55 TNF IL6 IL1B IL17A IL10 HLA-DRB1

Molecular functions related to Iridocyclitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.63 HLA-DRB1 HLA-DPB1 HLA-B
2 cytokine activity GO:0005125 9.44 VEGFA TNF IL6 IL1B IL17A IL10
3 MHC class II protein complex binding GO:0023026 9.43 HLA-DRB1 HLA-DPB1 CD4
Sources

Sources for Iridocyclitis

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....